SIBN SI-BONE

SI-BONE To Report Fourth Quarter 2022 Financial Results on February 27, 2023

SI-BONE To Report Fourth Quarter 2022 Financial Results on February 27, 2023

SANTA CLARA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2022 after market close on Monday, February 27, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: . Live audio of the webcast will be available on the “Investors” section of the company’s website at: . The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since 2009, when SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, over 3,000 surgeons have performed a combined total of more than 75,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two randomized controlled trials and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish near-universal coverage of minimally invasive SI joint fusion, including many payors that cover the procedure exclusively when performed with the iFuse Implant System. Supported by this proprietary reimbursement advantage, SI-BONE has actively leveraged its market leadership position in recent years to further clinical research, and evolve and commercialize novel surgical treatment solutions for SI-Joint pain, sacropelvic and pelvic fixation, and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit .

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Saqib Iqbal



EN
06/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SI-BONE

 PRESS RELEASE

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 an...

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing growth of 22.8%Gross margin of 79.8%, representing an improvement of 80 basis pointsNet loss of $6.2 million, representing an improvement of 31.2%Positive adjusted EBITDA of $1.0 million$145.5 million in cash and equ...

 PRESS RELEASE

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference ...

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this lin...

 PRESS RELEASE

SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2...

SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025 SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: . Live audio of the webcast will be availab...

 PRESS RELEASE

SI-BONE to Truist Securities MedTech Conference on June 17, 2025

SI-BONE to Truist Securities MedTech Conference on June 17, 2025 SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: . Live audio of the webcast wi...

 PRESS RELEASE

SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference ...

SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025 SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch